Active, not recruitingPhase 3NCT05059522
Continued Access Study for Participants Deriving Benefit in Pfizer-Sponsored Avelumab Parent Studies That Are Closing
Studying Malignant epithelial tumor of ovary
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Pfizer
- Principal Investigator
- Pfizer CT.gov Call CenterPfizer
- Intervention
- Avelumab(drug)
- Enrollment
- 68 enrolled
- Eligibility
- 18 years · All sexes
- Timeline
- 2021 – 2026
Study locations (30)
- Highlands Oncology Group, PA, Fayetteville, Arkansas, United States
- Highlands Oncology Group, PA, Rogers, Arkansas, United States
- Highlands Oncology Group, PA, Springdale, Arkansas, United States
- The Regents of the University of California, Los Angeles, California, United States
- UCLA Hematology/Oncology, Los Angeles, California, United States
- Moffitt Cancer Center, Tampa, Florida, United States
- MSK Basking Ridge, Basking Ridge, New Jersey, United States
- MSK Monmouth, Middletown, New Jersey, United States
- MSK Bergen, Montvale, New Jersey, United States
- MSK Commack, Commack, New York, United States
- MSK Westchester, Harrison, New York, United States
- Memorial Sloan Kettering Cancer Center (IDS Pharmacy), Long Island City, New York, United States
- Memorial Sloan Kettering Cancer Center - David H. Koch Center for Cancer Care (74th Street)., New York, New York, United States
- Memorial Sloan Kettering Cancer Center 53rd street., New York, New York, United States
- Memorial Sloan Kettering Cancer Center, New York, New York, United States
- +15 more locations on ClinicalTrials.gov
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT05059522 on ClinicalTrials.govOther trials for Malignant epithelial tumor of ovary
Additional recruiting or active studies for the same condition.
- RECRUITINGNCT07508306Patent Blue SLN in Early Ovarian Cancer Prospective Study (FIGO I-II) Evaluating Patent Blue SLN Mapping. Injection Into IP/UO Ligaments in Situ. Goals: Assess Feasibility and Accuracy vs Standard Lymphadenectomy to Minimize Surgical MorbidityFaculty of Medicine of Tunis
- RECRUITINGPHASE1NCT07524322Study of RGT-490 in Patients With PIK3CA-Mutated Advanced Solid TumorsRegor Pharmaceuticals Inc.
- RECRUITINGPHASE1NCT06366490Safety and Immunogenicity of Innocell Autologous Cellular Immunotherapy for Recurrent Epithelial Ovarian CancerPhotonPharma, Inc.
- RECRUITINGPHASE1NCT07402915Drug-drug Interaction Study With AZD5335 and Itraconazole in Participants With Ovarian, Primary Peritoneal, or Fallopian Tube CancerAstraZeneca
- RECRUITINGNANCT07280312Ultrasound Microvessel Imaging for the Evaluation of Ovarian and Adnexal LesionsMayo Clinic
- RECRUITINGPHASE2NCT07158021Leuprolide and Goserelin for Ovarian Function Suppression in Pre- or Peri-menopausal Women With Breast Cancer, OFS TrialUniversity of Michigan Rogel Cancer Center
- RECRUITINGPHASE2NCT06971744Autophagy Maintenance (AUTOMAIN)Medical University of South Carolina
- RECRUITINGPHASE3NCT06963268Validation of the Sentinel Lymph Node Technique in Early-stage Ovarian Cancer (SENTOV II)Instituto de Investigacion Sanitaria La Fe